{"id":44710,"date":"2022-06-04T21:02:06","date_gmt":"2022-06-04T19:02:06","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/cg-oncology-presents-new-clinical-data-on-two-ongoing-programs-at-the-american-society-of-clinical-oncology-asco-2022-annual-meeting\/"},"modified":"2022-06-04T21:02:06","modified_gmt":"2022-06-04T19:02:06","slug":"cg-oncology-presents-new-clinical-data-on-two-ongoing-programs-at-the-american-society-of-clinical-oncology-asco-2022-annual-meeting","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/cg-oncology-presents-new-clinical-data-on-two-ongoing-programs-at-the-american-society-of-clinical-oncology-asco-2022-annual-meeting\/","title":{"rendered":"CG Oncology Presents New Clinical Data on Two Ongoing Programs at The American Society of Clinical Oncology (ASCO) 2022 Annual Meeting"},"content":{"rendered":"
\n

\n– 92% (n=22\/24) of Evaluable Patients Achieved Complete Response (CR) at the Initial 3-Month Timepoint from the Phase 2 Clinical Trial of CG0070, an Oncolytic Immunotherapy, in Combination with KEYTRUDA\u00ae<\/sup> (pembrolizumab) for NMIBC Unresponsive to BCG –\n<\/p>\n

\n– Promising Preliminary Efficacy and Safety Data from the Phase 1b\/2 study of CG0070 in Combination with OPDIVO\u00ae (nivolumab), as a Neoadjuvant Immunotherapy for MIBC in Cisplatin-Ineligible Patients –\n<\/p>\n

IRVINE, Calif.–(BUSINESS WIRE)–#ASCO2022<\/a>—CG Oncology, Inc.<\/a>, a clinical-stage biotechnology company focused on developing oncolytic immunotherapies for patients with advanced cancer, today announced interim data on two ongoing clinical studies will be presented at The American Society of Clinical Oncology (ASCO) 2022 Annual Meeting.\n<\/p>\n

<\/a><\/p>\n

\nThe first poster presentation reports on efficacy and safety data from a global Phase 2 study (CORE1) of CG0070 in combination with Merck\u2019s anti-PD-1 therapy KEYTRUDA\u00ae<\/sup> (pembrolizumab), for the treatment of patients with Non-Muscle-Invasive Bladder Cancer (NMIBC) unresponsive to Bacillus Calmette-Guerin (BCG).\n<\/p>\n

\nThe second poster presentation centers on a Phase 1b\/2 study (CORE2) of CG0070 in combination with OPDIVO\u00ae(nivolumab), as a neoadjuvant immunotherapy for Muscle-Invasive Bladder Cancer (MIBC) in cisplatin-ineligible patients. This investigator-initiated study led by Dr. Roger Li at Moffitt Cancer Center in Tampa, Florida will summarize promising early data on safety and efficacy with the combination in this MIBC patient population.\n<\/p>\n

\n\u201cWe\u2019re excited to present these results at ASCO, which continue to support CG0070\u2019s promise in patients with bladder cancer unresponsive to BCG, a difficult-to-treat patient population,\u201d said Arthur Kuan, Chief Executive Officer, CG Oncology. \u201cWe hope to see continued positive results for CG0070 in combination with pembrolizumab in NMIBC patients unresponsive to BCG, and also, in future studies, show combination activity with nivolumab in MIBC patients who have limited treatment options.\u201d\n<\/p>\n

\n\u201cUsing an oncolytic virus to first engage an immune response and then amplifying that response with immune checkpoint blockade has shown exciting results in bladder cancer,\u201d said Roger Li, MD, lead study investigator and urologic oncologist at Moffitt Cancer Center. \u201cCG0070 may be a potential game changer to combat BCG-unresponsive bladder cancer.\u201d\n<\/p>\n

\nAbstract ID 4597: CORE1: Phase 2, single-arm study of CG0070 combined with pembrolizumab in patients with nonmuscle-invasive bladder cancer (NMIBC) unresponsive to bacillus Calmette-Guerin (BCG)<\/b>\n<\/p>\n

\nThe preliminary data for CORE1 adds to that presented at the American Urological Association (AUA)<\/a> and the American Association of Cancer Research (AACR)<\/a> Annual Meetings earlier this year and continues to show both promising early anti-tumor activity and tolerability of CG0070 in combination with pembrolizumab for patients with BCG unresponsive NMIBC.\n<\/p>\n